#Clarius Mobile Health #Ultrasound AI #FDA Clearances

Clarius Mobile Health's Breakthrough Year in 2025

Clarius Mobile Health, renowned for its innovative AI-powered handheld ultrasound technology, has announced a milestone year in 2025. The company reported reaching profitability while also achieving a robust 20% year-over-year revenue growth. This signifies not only a successful financial turnaround but also indicates Clarius's strategic transformation within the competitive landscape of medical imaging.

CEO Laurent Pelissier highlighted the intersection of commitment to clinical innovation and operational excellence as key factors leading to this milestone. "Achieving profitability while launching FDA-cleared AI models positions Clarius to secure the future of handheld ultrasound technology and enhances the sustainability of our operations," he asserted.

Expanding AI Capabilities and FDA Clearances

Throughout 2025, Clarius made significant strides in expanding its AI offerings with the introduction of two new FDA-cleared models integrated into the Clarius ultrasound application. This brings the total number of FDA-cleared models to six, alongside 16 AI technologies deployed across various medical applications. Notable advancements include the Clarius Prostate AI, which automates prostate identification and measurement for enhanced urological assessments, and Clarius Median Nerve AI, developed for improved diagnosis during carpal tunnel syndrome evaluations.

Global Recognition and Expansion Efforts

Clarius's innovative contributions to medical imaging garnered international acclaim, earning a place on TIME's list of the